Liu Yixin, Wang Su, Yang Feng, Chi Wenjing, Ding Li, Liu Tao, Zhu Feng, Ji Danian, Zhou Jun, Fang Yi, Zhang Jinghao, Xiang Ping, Zhang Yanmei, Zhao Hu
Department of Laboratory Medicine, Huadong Hospital, Fudan University, Shanghai, China.
Shanghai Key Laboratory of Clinical Geriatric Medicine, Shanghai, China.
Gut Pathog. 2022 Mar 30;14(1):14. doi: 10.1186/s13099-022-00488-y.
Shanghai, in east China, has one of the world's highest burdens of Helicobacter pylori infection. While multidrug regimens can effectively eradicate H. pylori, the increasing prevalence of antibiotic resistance (AR) in H. pylori has been recognized by the WHO as 'high priority' for urgent need of new therapies. Moreover, the genetic characteristics of H. pylori AR in Shanghai is under-reported. The purpose of this study was to determine the resistance prevalence, re-substantiate resistance-conferring mutations, and investigate novel genetic elements associated with H. pylori AR.
We performed whole genome sequencing and antimicrobial susceptibility testing of 112 H. pylori strains isolated from gastric biopsy specimens from Shanghai patients with different gastric diseases. No strains were resistant to amoxicillin. Levofloxacin, metronidazole and clarithromycin resistance was observed in 39 (34.8%), 73 (65.2%) and 18 (16.1%) strains, respectively. There was no association between gastroscopy diagnosis and resistance phenotypes. We reported the presence or absence of several subsystem protein coding genes including hopE, hofF, spaB, cagY and pflA, and a combination of CRISPRs, which were potentially correlated with resistance phenotypes. The H. pylori strains were also annotated for 80 genome-wide AR genes (ARGs). A genome-wide ARG analysis was performed for the three antibiotics by correlating the phenotypes with the genetic variants, which identified the well-known intrinsic mutations conferring resistance to levofloxacin (N87T/I and/or D91G/Y mutations in gyrA), metronidazole (I38V mutation in fdxB), and clarithromycin (A2143G and/or A2142G mutations in 23S rRNA), and added 174 novel variations, including 23 non-synonymous SNPs and 48 frameshift Indels that were significantly enriched in either the antibiotic-resistant or antibiotic-susceptible bacterial populations. The variant-level linkage disequilibrium analysis highlighted variations in a protease Lon with strong co-occurring correlation with a series of resistance-associated variants.
Our study revealed multidrug antibiotic resistance in H. pylori strains from Shanghai, which was characterized by high metronidazole and moderate levofloxacin resistance, and identified specific genomic characteristics in relation to H. pylori AR. Continued surveillance of H. pylori AR in Shanghai is warranted in order to establish appropriate eradication treatment regimens for this population.
中国东部的上海是世界上幽门螺杆菌感染负担最高的地区之一。虽然多药联合方案可以有效根除幽门螺杆菌,但幽门螺杆菌抗生素耐药性(AR)的日益普遍已被世界卫生组织认定为急需新疗法的“高度优先事项”。此外,上海幽门螺杆菌AR的基因特征报告不足。本研究的目的是确定耐药率,再次证实耐药相关突变,并研究与幽门螺杆菌AR相关的新基因元件。
我们对从上海不同胃部疾病患者的胃活检标本中分离出的112株幽门螺杆菌进行了全基因组测序和药敏试验。没有菌株对阿莫西林耐药。分别在39株(34.8%)、73株(65.2%)和18株(16.1%)菌株中观察到左氧氟沙星、甲硝唑和克拉霉素耐药。胃镜诊断与耐药表型之间没有关联。我们报告了几个子系统蛋白质编码基因(包括hopE、hofF、spaB、cagY和pflA)的存在与否,以及一系列成簇规律间隔短回文重复序列(CRISPRs),它们可能与耐药表型相关。这些幽门螺杆菌菌株还注释了80个全基因组AR基因(ARGs)。通过将表型与基因变异相关联,对这三种抗生素进行了全基因组ARG分析,确定了已知的赋予左氧氟沙星耐药性的内在突变(gyrA中的N87T/I和/或D91G/Y突变)、甲硝唑耐药性(fdxB中的I38V突变)和克拉霉素耐药性(23S rRNA中的A2143G和/或A2142G突变),并增加了174个新变异,包括23个非同义单核苷酸多态性(SNPs)和48个移码插入缺失,这些变异在抗生素耐药或抗生素敏感细菌群体中显著富集。变异水平的连锁不平衡分析突出了一种蛋白酶Lon中的变异,其与一系列耐药相关变异具有强烈的共现相关性。
我们的研究揭示了上海幽门螺杆菌菌株的多药耐药性,其特征是甲硝唑耐药率高,左氧氟沙星耐药率中等,并确定了与幽门螺杆菌AR相关的特定基因组特征。有必要对上海的幽门螺杆菌AR进行持续监测,以便为该人群制定合适的根除治疗方案。